CORONABSECORONA REMEDIES LIMITEDMediumNeutral
Announced Wed, 30 Sept, 2026 · 19:16 IST

CARE upgrades short-term rating to A1 plus; reaffirms long-term at A plus Stable

Rating UpgradedCredit & Debt View source PDFExplain this filing

CORONA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-3.3%1-day move
₹2100.00
prior close
₹2093.30
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.6-1.6-1.4-1.1-3.3-3.1-2.8-4.8——————
Up moveDown movePending
AI summary

CARE Ratings has upgraded Corona Remedies' short-term bank facility rating to CARE A1+ (highest grade) from CARE A1, while reaffirming the long-term rating at CARE A+ with a Stable outlook. The upgrade applies to about Rs.70 crore of long-term and short-term bank facilities from ICICI Bank (Rs.50 crore) and Citi Bank (Rs.20 crore). The long-term rating on a Rs.7 crore Citi Bank term loan (reduced from Rs.25 crore as it gets repaid) was reaffirmed. Review was based on audited FY26 and unaudited Q1FY27 results.

Likely market impact

Positive for shareholders - upgrade to the top short-term rating signals strong financial health and smooth debt servicing capacity.